At a glance
A tuftsin-related peptide discussed in intranasal research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The current source emphasizes human intranasal studies and measured actuator output. Nasal drops, sprays and systemic administration should not be treated as equivalent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Selank.
A comprehensive adverse-effect profile is not established by the source record. Consult the cited studies for what was measured and what remains uncertain.
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 4 source tables
Selank 5 mg Nasal Spray Calculations
| Measured Final Volume | Vehicle Added After Transfer | Final Concentration | Per Verified 0.10 mL Spray |
|---|---|---|---|
| 5.0 mL | About 2.0 mL | 1,000 mcg/mL | 100 mcg50 nominal sprays |
| 10.0 mL | About 7.0 mL | 500 mcg/mL | 50 mcg100 nominal sprays |
Both options begin with 3.0 mL in the peptide vial. Transfer the complete solution, then add enough vehicle to reach the measured final volume. Calculation basis: Each row uses the full 5 mg vial and a pump verified to release 0.10 mL per complete actuation. Nominal spray counts are calculated before priming and normal residual hold-up.
Mathematical Actuator Equivalents
| Literature Amount | 5 mL Option100 mcg per Spray | 10 mL Option50 mcg per Spray |
|---|---|---|
| 300 mcg | 3 sprays | 6 sprays |
| 900 mcg | 9 sprays | 18 sprays |
| 2,700 mcg | 27 sprays | 54 sprays |
These rows are concentration conversions, not a universal schedule. The larger actuation counts show why amounts reported with a manufactured drop formulation should not be treated as direct generic-pump instructions. Use the measured final volume and verified actuator output in every calculation. Bottle capacity alone does not establish the final volume or the amount delivered per spray.
Published Human Intranasal Selank Research
| Source | Research Context | Published Intranasal Amount and Formulation |
|---|---|---|
| Zozulia et al., 2008[1] | 62 adults with generalized anxiety disorder or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14. |
| Syunyakov et al., 2012[2] | 20 adults with generalized anxiety disorder | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure. |
| Panikratova et al., 2020[3] | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount. |
Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable. The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days[4]. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump. Reference concentration: Mathematically, 5 mg brought to about 3.33 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.
Core Formula
| Verified Actuator Output | 5 mL Option1,000 mcg/mL | 10 mL Option500 mcg/mL |
|---|---|---|
| 0.05 mL | 50 mcg | 25 mcg |
| 0.10 mL | 100 mcg | 50 mcg |
| 0.13 mL | 130 mcg | 65 mcg |
mcg per spray = (5,000 mcg / final volume in mL) x verified mL per spray nominal sprays = final volume in mL / verified mL per spray
Additional schedule context & duration
Quick reference for the intranasal Selank 5 mg calculation.
- Human research route: Intranasal drops or solution.
- Peptide amount: 5,000 mcg total in the vial.
- 5 mL option: 1,000 mcg/mL and 100 mcg per verified 0.10 mL spray.
- 10 mL option: 500 mcg/mL and 50 mcg per verified 0.10 mL spray.
- Final-volume rule: Bring the transferred solution to an exact measured final volume.
Preparation
How to Prepare the 5 mL or 10 mL Research Bottle
- Confirm the 5 mg vial, selected sterile research vehicle, actuator bottle capacity, and documented pump output.
- Add 3.0 mL of compatible sterile vehicle to the vial with aseptic transfer technique.
- Gently swirl until the contents are dissolved. Do not shake.
- Transfer the complete 3.0 mL solution into a sterile 5 mL or 10 mL nasal actuator bottle.
- Add enough vehicle to reach a measured final volume of exactly 5.0 mL or 10.0 mL. The theoretical additions are approximately 2.0 mL and 7.0 mL.
- Secure the pump and label the bottle with the peptide amount, final volume, concentration, pump output, and preparation date.
- Prime the pump according to the actuator instructions and record the priming sprays in the research log.
Vehicle context: The worked example can use sterile 0.9% saline as a research vehicle. The registered 0.15% Selank product contains 1.5 mg/mL Selank in purified water with methylparaben, so the saline example is not the same as the manufactured multidose drop formulation[4].
Storage Instructions
Storage depends on the complete formulation, container, and handling method.
- Registered 0.15% product: Protected from light, stored at no more than 10 degrees C, and not frozen[4].
- Opened registered product: The manufacturer permits storage at no more than 25 degrees C for up to 15 days[4].
- Custom research preparation: Use formulation-specific stability and microbiological controls rather than transferring the finished-product shelf life.
- Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.
Nasal Actuator Technique
Use a standardized device procedure so the recorded amount remains consistent across research observations.
- Inspect the labeled concentration and confirm the actuator output before use.
- Prime or reprime the pump according to the manufacturer instructions.
- Keep the bottle in the specified orientation and use one complete, smooth stroke.
- Record each actuation immediately, including priming sprays.
- Wipe the nozzle with a clean material appropriate for the device and replace the cap.
- Return the bottle to its documented storage condition after the research procedure.
Materials & quantity planning
Source materials checklist · 5 mg
Use one complete set of measured and sterile research supplies for each prepared Selank 5 mg nasal bottle.
- Selank 5 mg research vial: One vial per prepared bottle, with lot-specific identity, purity, and assay documentation. The supplier card below links to the existing Selank 5 mg product page.
- Sterile research vehicle: Single-use sterile 0.9% sodium chloride for the worked saline example, or another validated sterile nasal research vehicle.
- Sterile nasal actuator bottle: One 5 mL or 10 mL bottle intended for single-user research.
- Metered pump: A compatible actuator documented or verified at 0.10 mL per complete spray.
- Calibrated transfer tools: Sterile syringes or pipettes that can measure the initial 3.0 mL and the exact 5.0 mL or 10.0 mL final volume.
- Sterile transfer needle: Required when the peptide vial uses a rubber septum.
- Clean handling supplies: Alcohol preparation pads, clean gloves, and a disinfected work surface.
- Label and research log: Record the peptide amount, final volume, concentration, pump output, preparation date, priming sprays, and actuation count.
- Storage materials: Light-protective, temperature-controlled storage appropriate to the validated formulation.
- Sharps container: Use when transfer needles are part of the preparation workflow.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
Continue exploring
Related topics are not interchangeable compounds or formulations.